Cyclic dinucleotide metal compound, and preparation and application thereof
US-2024317792-A1 · Sep 26, 2024 · US
Ionic cocrystal of lithium, lispro, for the treatment of fragile X syndrome
US10098909B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10098909-B2 |
| Application number | US-201715425367-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 6, 2017 |
| Priority date | Feb 5, 2016 |
| Publication date | Oct 16, 2018 |
| Grant date | Oct 16, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates to a pharmaceutical composition comprising an ionic co-crystal (ICC) of lithium with salicylic acid and 1-proline (LISPRO). The pharmaceutical composition can further comprise an anti-inflammatory agent, for example, salicylic acid. An embodiment of the invention provides a method for treating Fragile X Syndrome (FXS) in a subject by administering to the subject a composition comprising a pharmaceutically effective amount of LISPRO.
First claim
Opening claim text (preview).
We claim: 1. A method for treating Fragile X Syndrome (FXS) in a subject in need thereof, the method comprising orally administering to the subject a composition comprising a pharmaceutically effective amount of an ionic co-crystal of lithium with salicylic acid and 1-praline (LISPRO) for at least two months, wherein the pharmaceutically effective amount is 45 mg/kg/day to 50 mg/kg/day. 2. The method of claim 1 , wherein the composition further comprises an anti-inflammatory agent. 3. The method of claim 2 , wherein the anti-inflammatory agent a steroidal anti-inflammatory agent or a non-steroidal anti-inflammatory agent. 4. The method of claim 1 , wherein the pharmaceutically effective amount of LISPRO produces lithium concentration in the plasma of the subject over about 2 hours to about 3 days at about 0.5 μg/ml to about 5 μg/ml. 5. The method of claim 1 , wherein the pharmaceutically effective amount of LISPRO produces lithium concentration in the brain of the subject over about 2 hours to about 3 days at about 0.5 μg/ml to about 5 μg/ml. 6. The method of claim 1 , wherein LISPRO is administered daily to a subject at about 45 mg/kg. 7. The method of claim 1 , wherein LISPRO is administered daily to a subject at about 50 mg/kg. 8. The method of claim 1 , wherein the pharmaceutically effective amount of LISPRO produces lithium concentration in the plasma of the subject over about 2 hours to about 3 days at about 0.75 μg/ml to about 4 μg/ml. 9. The method of claim 1 , wherein the pharmaceutically effective amount of LISPRO produces lithium concentration in the plasma of the subject over about 2 hours to about 3 days at about 1 μg/ml to about 3 μg/ml. 10. The method of claim 1 , wherein the pharmaceutically effective amount of LISPRO produces lithium concentration in the brain of the subject over about 2 hours to about 3 days at about 0.75 μg/ml to about 4 μg/ml. 11. The method of claim 1 , wherein the pharmaceutically effective amount of LISPRO produces lithium concentration in the brain of the subject over about 2 hours to about 3 days at about 1 μg/ml to about 3 μg/ml. 12. The method of claim 1 , comprising administering LISPRO to the subject for two months.
Assignees
Inventors
Classifications
Proline; Derivatives thereof, e.g. captopril · CPC title
- A61K33/00Primary
Medicinal preparations containing inorganic active ingredients · CPC title
Salicylic acid; Derivatives thereof · CPC title
Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10098909B2 cover?
- The invention relates to a pharmaceutical composition comprising an ionic co-crystal (ICC) of lithium with salicylic acid and 1-proline (LISPRO). The pharmaceutical composition can further comprise an anti-inflammatory agent, for example, salicylic acid. An embodiment of the invention provides a method for treating Fragile X Syndrome (FXS) in a subject by administering to the subject a composit…
- Who is the assignee on this patent?
- Tan Jun, Shytle Roland Douglas, Univ South Florida
- What technology area does this patent fall under?
- Primary CPC classification A61K33/00. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Oct 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).